Skip to main content
Top
Published in: Respiratory Research 1/2020

Open Access 01-12-2020 | Cough | Letter to the Editor

Laryngopharyngeal reflux in chronic obstructive pulmonary disease - a multi-centre study

Authors: Julia Sanchez, Desiree M. Schumann, Meropi Karakioulaki, Eleni Papakonstantinou, Frank Rassouli, Matthias Frasnelli, Martin Brutsche, Michael Tamm, Daiana Stolz

Published in: Respiratory Research | Issue 1/2020

Login to get access

Abstract

Reflux of gastric content has been associated with recurrent exacerbations of chronic obstructive pulmonary disease (COPD). We aimed to assess the prevalence of laryngopharyngeal reflux (LPR) in COPD and if LPR is a contributing factor to clinically relevant outcomes in COPD. We evaluated a total of 193 COPD patients (GOLD I-IV) with a 24-h laryngo-pharyngeal pΗ-monitor. LPR was observed in 65.8% of COPD patients and it was not significantly associated with clinically relevant outcomes of COPD. Treatment with PPI significantly decreased the upright RYAN score (p = 0.047) without improving lung function. Furthermore, the presence or severity of LPR cannot be diagnosed based solely on symptoms and questionnaires.
Appendix
Available only for authorised users
Literature
2.
go back to reference Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165–85.CrossRef Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165–85.CrossRef
3.
go back to reference Celli BR, MacNee W. ATS/ERS task force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932–46.CrossRef Celli BR, MacNee W. ATS/ERS task force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932–46.CrossRef
4.
go back to reference Clini EM, Boschetto P, Lainscak M, Janssens W. Comorbidities in chronic obstructive pulmonary disease from assessment to treatment. Biomed Res Int. 2014;2014:414928. Clini EM, Boschetto P, Lainscak M, Janssens W. Comorbidities in chronic obstructive pulmonary disease from assessment to treatment. Biomed Res Int. 2014;2014:414928.
5.
go back to reference Nussbaumer-Ochsner Y, Rabe KF. Systemic manifestations of COPD. Chest. 2011;139(1):165–73.CrossRef Nussbaumer-Ochsner Y, Rabe KF. Systemic manifestations of COPD. Chest. 2011;139(1):165–73.CrossRef
6.
go back to reference Pratter MR. Overview of common causes of chronic cough: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1 Suppl):59S–62S.CrossRef Pratter MR. Overview of common causes of chronic cough: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1 Suppl):59S–62S.CrossRef
7.
go back to reference Baumeler L, Papakonstantinou E, Milenkovic B, Lacoma A, Louis R, Aerts JG, et al. Therapy with proton-pump inhibitors for gastroesophageal reflux disease does not reduce the risk for severe exacerbations in COPD. Respirology. 2016;21(5):883–90.CrossRef Baumeler L, Papakonstantinou E, Milenkovic B, Lacoma A, Louis R, Aerts JG, et al. Therapy with proton-pump inhibitors for gastroesophageal reflux disease does not reduce the risk for severe exacerbations in COPD. Respirology. 2016;21(5):883–90.CrossRef
8.
go back to reference Sakae TM, Pizzichini MM, Teixeira PJ, Silva RM, Trevisol DJ, EP. Exacerbations of COPD and symptoms of gastroesophageal reflux: a systematic review and meta-analysis. J Bras Pneumol. 2013;39(3):259–71.CrossRef Sakae TM, Pizzichini MM, Teixeira PJ, Silva RM, Trevisol DJ, EP. Exacerbations of COPD and symptoms of gastroesophageal reflux: a systematic review and meta-analysis. J Bras Pneumol. 2013;39(3):259–71.CrossRef
9.
go back to reference Rascon-Aguilar IE, Pamer M, Wludyka P, Cury J, Coultas D, Lambiase LR, et al. Role of gastroesophageal reflux symptoms in exacerbations in COPD. Chest. 2006;130(4):1096–101.CrossRef Rascon-Aguilar IE, Pamer M, Wludyka P, Cury J, Coultas D, Lambiase LR, et al. Role of gastroesophageal reflux symptoms in exacerbations in COPD. Chest. 2006;130(4):1096–101.CrossRef
10.
go back to reference Lin YH, Tsai CL, Chien LN, Chiou HY, Jeng C. Newly diagnosed gastroesophageal reflux disease increased the risk of acute exacerbation of chronic obstructive pulmonary disease during the first year following diagnosis - a nationwide population-based cohort study. Int J Clin Pract. 2015;69(3):350–7.CrossRef Lin YH, Tsai CL, Chien LN, Chiou HY, Jeng C. Newly diagnosed gastroesophageal reflux disease increased the risk of acute exacerbation of chronic obstructive pulmonary disease during the first year following diagnosis - a nationwide population-based cohort study. Int J Clin Pract. 2015;69(3):350–7.CrossRef
11.
go back to reference Casanova C., Baudet JS., del VAlle Velasco M., Martin JM., Aguirre-Jaime A., de Torres JP., et al. Increased gastro-oesophageal reflux disease in patients with severe COPD. Eur Respir J 2004;23(6):841–845. Casanova C., Baudet JS., del VAlle Velasco M., Martin JM., Aguirre-Jaime A., de Torres JP., et al. Increased gastro-oesophageal reflux disease in patients with severe COPD. Eur Respir J 2004;23(6):841–845.
12.
go back to reference Iliaz S, Iliaz R, Onur ST, Arici S, Akyuz U, Karaca C, et al. Does gastroesophageal reflux increase chronic obstructive pulmonary disease exacerbations? Respir Med. 2006;115:20–5.CrossRef Iliaz S, Iliaz R, Onur ST, Arici S, Akyuz U, Karaca C, et al. Does gastroesophageal reflux increase chronic obstructive pulmonary disease exacerbations? Respir Med. 2006;115:20–5.CrossRef
13.
go back to reference Hamdan AL, Ziade G, Turfe Z, Beydoun N, Sarieddine D, Kanj N. Laryngopharyngeal symptoms in patients with chronic obstructive pulmonary disease. Eur Arch Otorhinolaryngol. 2016;273:953–8.CrossRef Hamdan AL, Ziade G, Turfe Z, Beydoun N, Sarieddine D, Kanj N. Laryngopharyngeal symptoms in patients with chronic obstructive pulmonary disease. Eur Arch Otorhinolaryngol. 2016;273:953–8.CrossRef
14.
go back to reference Oelschlager BK, Chang L, Pope CE 2nd., Pellegrini CA. Typical GERD Symptoms and esophageal pH monitoring are not enough to diagnose pharyngeal reflux. J Surg Res. 2005;128(1):55–60.CrossRef Oelschlager BK, Chang L, Pope CE 2nd., Pellegrini CA. Typical GERD Symptoms and esophageal pH monitoring are not enough to diagnose pharyngeal reflux. J Surg Res. 2005;128(1):55–60.CrossRef
15.
go back to reference Hamdan AL, Jaffal H, Btaiche R, Turfe ZA, Bawab I, Kanj N, et al. Laryngopharyngeal symptoms in patients with asthma: a cross-sectional controlled study. Clin Respir J. 2016;10:40–7.CrossRef Hamdan AL, Jaffal H, Btaiche R, Turfe ZA, Bawab I, Kanj N, et al. Laryngopharyngeal symptoms in patients with asthma: a cross-sectional controlled study. Clin Respir J. 2016;10:40–7.CrossRef
16.
go back to reference Ylitalo R, Thibeault SL. Relationship between time of exposure of laryngopharyngeal reflux and gene expression in laryngeal fibroblasts. Ann Otol Rhinol Laryngol. 2006;115(10):775–83.CrossRef Ylitalo R, Thibeault SL. Relationship between time of exposure of laryngopharyngeal reflux and gene expression in laryngeal fibroblasts. Ann Otol Rhinol Laryngol. 2006;115(10):775–83.CrossRef
17.
go back to reference Jung YH, Lee DY, Kim DW, Park SS, Heo EY, Chung HS, et al. Clinical significance of laryngopharyngeal reflux in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:1343–51.PubMedPubMedCentral Jung YH, Lee DY, Kim DW, Park SS, Heo EY, Chung HS, et al. Clinical significance of laryngopharyngeal reflux in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:1343–51.PubMedPubMedCentral
18.
go back to reference Eryuksel E, Dogan M, Olgun S, Kocak I, Celikel T. Incidence and treatment results of laryngopharyngeal reflux in chronic obstructive pulmonary disease. Eur Arch Otorhinolaryngol. 2009;266(8):1267–71.CrossRef Eryuksel E, Dogan M, Olgun S, Kocak I, Celikel T. Incidence and treatment results of laryngopharyngeal reflux in chronic obstructive pulmonary disease. Eur Arch Otorhinolaryngol. 2009;266(8):1267–71.CrossRef
19.
go back to reference Benson VS, Mullerova H, Vestbo J, Wedzicha JA, Patel A, Hurst JR, et al. Associations between gastro-oesophageal reflux, its management and exacerbations of chronic obstructive pulmonary disease. Respir Med. 2015;109(9):1147–54.CrossRef Benson VS, Mullerova H, Vestbo J, Wedzicha JA, Patel A, Hurst JR, et al. Associations between gastro-oesophageal reflux, its management and exacerbations of chronic obstructive pulmonary disease. Respir Med. 2015;109(9):1147–54.CrossRef
20.
go back to reference Ayazi S, Lipham JC, Hagen JA, Tang AL, Zehetner J, Leers JM, et al. A new technique for measurement of pharyngeal pH: normal values and discriminating pH threshold. J Gastrointest Surg. 2009;13(8):1422–9.CrossRef Ayazi S, Lipham JC, Hagen JA, Tang AL, Zehetner J, Leers JM, et al. A new technique for measurement of pharyngeal pH: normal values and discriminating pH threshold. J Gastrointest Surg. 2009;13(8):1422–9.CrossRef
21.
go back to reference Stolz D, Papakonstantinou E, Grize L, Schilter D, Strobel W, Louis R, et al. Time-course of upper respiratory tract viral infection and COPD exacerbation. Eur Respir J. 2019;54(4):1900407. Stolz D, Papakonstantinou E, Grize L, Schilter D, Strobel W, Louis R, et al. Time-course of upper respiratory tract viral infection and COPD exacerbation. Eur Respir J. 2019;54(4):1900407.
22.
go back to reference Stolz D, Hirsch HH, Schilter D, Louis R, Rakic J, Boeck L, et al. Intensified therapy with inhaled corticosteroids and long-acting β(2)-agonists at the onset of upper respiratory tract infection to Prevent chronic obstructive pulmonary disease exacerbations. A multicenter, randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2018;197(9):1136–46.CrossRef Stolz D, Hirsch HH, Schilter D, Louis R, Rakic J, Boeck L, et al. Intensified therapy with inhaled corticosteroids and long-acting β(2)-agonists at the onset of upper respiratory tract infection to Prevent chronic obstructive pulmonary disease exacerbations. A multicenter, randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2018;197(9):1136–46.CrossRef
23.
go back to reference Kilic M, Ozturk F, Kirmemis O, Atmaca S, Guner SN, Caltepe G, et al. Impact of laryngopharyngeal and gastroesophageal reflux on asthma control in children. Int J Pediatr Otorhinolaryngol. 2013;77(3):341–5.CrossRef Kilic M, Ozturk F, Kirmemis O, Atmaca S, Guner SN, Caltepe G, et al. Impact of laryngopharyngeal and gastroesophageal reflux on asthma control in children. Int J Pediatr Otorhinolaryngol. 2013;77(3):341–5.CrossRef
24.
go back to reference Wang G, Qu C, Wang L, Liu H, Han H, Xu B, et al. Utility of 24-hour pharyngeal pH monitoring and clinical feature in laryngopharyngeal reflux disease. Acta Otolaryngol. 2019;139(3):299–303.CrossRef Wang G, Qu C, Wang L, Liu H, Han H, Xu B, et al. Utility of 24-hour pharyngeal pH monitoring and clinical feature in laryngopharyngeal reflux disease. Acta Otolaryngol. 2019;139(3):299–303.CrossRef
25.
go back to reference Broers C, Tack J, Pauwels A. Review article: gastro-oesophageal reflux disease in asthma and chronic obstructive pulmonary disease. Aliment Pharmacol Ther. 2018;47(2):176–91.CrossRef Broers C, Tack J, Pauwels A. Review article: gastro-oesophageal reflux disease in asthma and chronic obstructive pulmonary disease. Aliment Pharmacol Ther. 2018;47(2):176–91.CrossRef
26.
go back to reference Morice AH, Millqvist E, Bieksiene K, Birring SS, Dicpinigaitis P, Domingo Ribas C, et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J. 2020;55(1):1901136. Morice AH, Millqvist E, Bieksiene K, Birring SS, Dicpinigaitis P, Domingo Ribas C, et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J. 2020;55(1):1901136.
Metadata
Title
Laryngopharyngeal reflux in chronic obstructive pulmonary disease - a multi-centre study
Authors
Julia Sanchez
Desiree M. Schumann
Meropi Karakioulaki
Eleni Papakonstantinou
Frank Rassouli
Matthias Frasnelli
Martin Brutsche
Michael Tamm
Daiana Stolz
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2020
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-020-01473-2

Other articles of this Issue 1/2020

Respiratory Research 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine